Qprotyn - Model HILOPRO - Cutting Edge, Viscosity-Reduction Technology for Monoclonal Antibodies

The HILOPRO technology uses patented platform technology with GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance. This single formulation technology works for a wide range of monoclonal antibodies, supports multiple dosing and delivery options providing greater flexibility and optimal patient convenience.